# Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke

Study · id `cardio:ct-nct07301372` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07301372](<https://clinicaltrials.gov/study/NCT07301372>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07301372

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT07301372. Randomized; single masking; primary purpose treatment. Start 2025-10-30 (actual); primary completion 2026-03-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT07301372, source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)
- Started: 2025-10-30 (actual) (ClinicalTrials.gov record NCT07301372, source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2026-03-08 (actual) (ClinicalTrials.gov record NCT07301372, source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)
- Completion: 2026-06-01 (actual) (ClinicalTrials.gov record NCT07301372, source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07301372, source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07301372-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke
- Acronym: EPOCH-LYSIS
- Condition: Acute Stroke
- Intervention (Drug): Ivolumab 420mg (three vials)
- Lead sponsor: The Affiliated Hospital of Xuzhou Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The Affiliated Hospital of Xuzhou Medical University (`cardio:org-the-affiliated-hospital-of-xuzhou-medical-university`)

## Provenance

Content hash: 694dedf9020e43afba58f2ef7c4fc01af5b5c75e01acfd3d0d4fc24e0bccf6fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
